Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling. - Barron's

Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling. - Barron's
Business

Listen to this article

0%

Replimune Groupreceived Food and Drug Administration clearance for its skin cancer drug, concluding a saga that saw regulators twice deny its application. The stock was falling anyway. Copyright Β©20… [+84 chars]

Leave A Comment

Comments are moderated and may take time to appear.

Comments

No comments yet. Be the first to comment!

Stay Connected